RESEARCH ADMINISTRATION

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 佛罗里达A&M大学（FAMU）少数民族研究中心（RCMI）计划包括四个（4）自我永存的核心：生物技术”疾病预防和治疗的途径;药物发现-提供策略，以开发可用于治疗神经退行性疾病的新药候选人;神经退行性疾病-为研究人员提供对直接和间接神经毒性的理解;和纳米医学-在纳米粒子技术领域建立资源和专业知识）和一个行政组成部分，促进跨学科的研究合作和知识转移，导致教师提交独立的研究建议。这些核心将为大学教职员工提供在组织内部和外部的几个层面上开展合作研究活动的能力。 RCMI计划为三个创新研究试点项目提供支持，以增加少数民族科学家作为独立调查人员的数量，并进一步发展和加强大学的研究基础设施。 教师研究人员从事的研究活动包括：局部神经炎性抑制剂的开发; HHV-6抑制：慢性疲劳的影响;吸入，局部，透皮，鼻腔和大脑药物递送;纳米医学与翻译结果;纳米颗粒药物递送;潜在抗癌和抗微生物剂的合成和药理学评价;有机硫化合物对B（a）P诱导的细胞转化的预防;作为皮肤刺激的体外模型的Epidermal FT-200培养物的评价; Escherichia coli凝胶制剂的评价;通过人皮肤的体外透皮吸收;肺癌治疗的新方法;铅/锰：原代神经元中的细胞信号和基因表达;酯酶在异戊烯化生物化学中的意义; JP-8中选定化学物质对大鼠皮肤刺激和免疫抑制的研究;具有氯氮平样多巴胺能结合剂的合成和评价;新型局部抗炎甾体的合成与评价; β淀粉样蛋白在神经元中的摄取与降解机制。亨利刘易斯三世博士担任主要研究者，Karam F.A.博士担任主要研究者。Soliman担任项目总监。 具体目标（具体目标没有变化） 1.继续提供行政监督，以加强RCMI计划的赠款管理和研究发展 2.招聘和雇用药剂学领域的教员 3.提供指导计划 4.举办科学研讨会 5.提供教师发展研究经费 6.提供讲习班和培训 7.加强主流资金的获取： 8.为持续改进提供RCMI评估计划：

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Florida A&M University (FAMU) Research Center in Minority Institutions (RCMI) Program consist of four (4) self-perpetuating Cores: Biotechnology" Pathways to Disease Prevention and Therapy; Drug Discovery - provide strategies to develop novel drug candidates that can be used for the treatment of neurodegenerative diseases; Neurodegeneration - provides researchers with an understanding of the direct and indirect neurotoxicity; and Nanomedicine - establishing resources and expertise in the area of nanoparticles technology) and an administrative component which facilitate interdisciplinary research collaboration and knowledge transfer leading to faculty submission of independent-research proposals. These Cores will provide University faculty members with the ability to embark on collaborative research activities at several levels internal and external to the organization. The RCMI Program provide support for three innovative research pilot projects in an effort to increase the number of minority scientists as independent investigators and further develop and enhance the University research infrastructure. Faculty investigators are engaged in research activities involving: Development of Topical Neuroinflammatory Inhibitors; HHV-6 Inhibition: Implications in Chronic Fatigue; Inhalation, topical, transdermal, nasal, and brain drug delivery; Nanomedicine with translational outcomes; Nanoparticle Drug Delivery; Synthesis and Pharmacological Evaluations of Potential Anti-Cancer and Anti Microbial Agents; Prevention of B(a)P Induced Cell Transformation by Organosulfur Compounds; Evaluation of Epiderm FT-200) culture as an in vitro model for skin irritation; Evaluations of formulations of Estradiol Gels; In Vitro Percutaneous Absorption of Testosterone through Human Skin; Novel Approaches in the Treatment of Lung Cancer; Pb/Mn: Cell Signaling and Gene Expression in Primary Neurons; Significance of Esterases in Prenylation Biochemistry; Studies on Skin Irritation and Immune Suppression of Selected Chemicals of JP-8 in rats; Synthesis and Evaluation of Agents with Clozapine-Like Dopaminergic Binding; Synthesis and Evaluation of New Local Anti-Inflammatory Steroids; and Uptake Mechanisms and Degradation of Amyloid Beta Protein in Neurons. Dr. Henry Lewis III serves as principal investigator and Dr. Karam F.A. Soliman serves as Program Director. Specific Aims (There are no changes in the specific aims) 1. Continue to provide administrative oversight to enhance the grants management and research development of the RCMI Programs 2. Recruit and hire a faculty member in the area of pharmaceutics 3. Provide mentoring program 4. Provide scientific seminars 5. Provide faculty development research funding 6. Provide workshops and training 7. Enhance the acquisition of mainstream funding: 8. Provide an RCMI evaluation plan for continues improvement: